Dr. Allitia DiBernardo, M.D., Vice President, Global Medical Affairs, Neuroscience, Global Commercial Strategy Organization (GCSO) at Janssen discusses a novel patient recruitment strategy for patients with multiple sclerosis that was presented at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS ®) 2022 meeting. Janssen will be utilizing up-front matching to assign patients treatments as if they were being randomized to treatment. This unique design tactic is especially of value for studies whose results become part of the evidence for regulatory decision-making to be more credible with the potential for significant cost efficiencies in generating the data.
With over 22 years of experience in the field, I am passionate about understanding and shining a light on the lived experiences of individuals with neurologic disorders. As the Global Head of Medial Affairs, Neurology at Janssen, I have the honor of channeling that passion into leading an incredible team that is actively working to bring new therapies to patients with CNS disorders, leading the way in neurology research.